QUCY Quantum Cyber N.V.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1874252 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-0.2%
TTM net income YoY18.0%
TTM EPS YoY66.2%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—
Margins
Gross margin64.3%
Operating margin-2,099.9%
Net margin-2,416.0%
FCF margin-1,950.2%
EBITDA margin-2,022.0%
Returns
ROE-462.0%
ROA-149.4%
ROIC (approx.)—
Asset turnover0.06x
Leverage & solvency
Liabilities / assets55.6%
Debt / equity0.00x
Current ratio1.30x
Interest coverage-19.85x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue11.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $537,080 | $893,991 | $895,479 | $529,877 | $577,348 |
| Cost of revenue | $147,288 | $319,108 | $385,820 | $347,726 | $399,726 |
| Gross profit | $389,792 | $574,883 | $509,659 | $182,151 | $177,622 |
| R&D expense | $4.91M | $5.72M | $9.59M | $5.02M | $481,934 |
| SG&A expense | $5.11M | $6.65M | $11.41M | $15.21M | $8.46M |
| Operating income | -$16.14M | -$18.77M | -$26.64M | -$26.44M | -$9.72M |
| Interest expense | $373,458 | $945,545 | $522,400 | $242,020 | $339,171 |
| Pretax income | -$16.21M | -$21.60M | -$26.30M | -$26.39M | -$11.69M |
| Net income | -$16.21M | -$21.60M | -$26.34M | -$26.39M | -$11.69M |
| EBITDA | -$15.52M | -$18.08M | -$25.78M | -$26.06M | -$9.65M |
| EPS (basic) | -2.70 | -21.91 | -64.76 | -74.55 | -1.62 |
| EPS (diluted) | -2.70 | -21.91 | -64.76 | -74.55 | -1.62 |
| Weighted avg. shares (diluted) | 6.00M | 985,717 | — | 14.16M | 7.21M |
| Banking | |||||
| Net interest income | — | -$39,817 | -$152,562 | -$65,389 | — |
| Balance sheet | |||||
| Cash & equivalents | $701,602 | $6.24M | $7.07M | $17.14M | $8.73M |
| Receivables | — | $33,577 | $93,555 | $0 | $111,842 |
| Inventory | $216,888 | $372,870 | $613,638 | $175,469 | — |
| Current assets | $4.21M | $8.02M | $8.98M | $18.38M | $9.61M |
| PP&E, net | $1.09M | $1.37M | $1.70M | $661,692 | $37,884 |
| Intangibles | $1.11M | $3.02M | $3.39M | — | $1.20M |
| Total assets | $5.33M | $13.50M | $15.41M | $20.24M | $10.04M |
| Current liabilities | $4.69M | $6.18M | $9.24M | $4.24M | $1.35M |
| Short-term debt | $956,902 | $1.02M | — | $959,116 | $22,754 |
| Total liabilities | $4.69M | $7.50M | $12.16M | $6.14M | $3.68M |
| Shareholders' equity | $641,600 | $6.00M | $3.35M | $14.10M | $6.36M |
| Shares outstanding | 9.78M | 2.32M | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$10.98M | -$17.33M | -$21.94M | -$14.77M | -$3.22M |
| Capital expenditure | $1,216 | $104,949 | $1.20M | $658,483 | $16,705 |
| Free cash flow | -$10.98M | -$17.43M | -$23.14M | -$15.43M | -$3.24M |
| Investing cash flow | -$1.03M | -$198,817 | -$1.90M | -$658,483 | $1.20M |
| Financing cash flow | $6.76M | $16.79M | $14.23M | $23.94M | $10.61M |
| Depreciation & amortization | $615,720 | $696,629 | $866,412 | $379,798 | $69,929 |
| Stock-based compensation | $1.47M | -$63,117 | $4.01M | $9.82M | $6.43M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.